Cochrane neurological network corner
Commentary on “Immunosuppressant drugs for myasthenia gravis”
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
View Full Text
The choice of treatments for this chronic, disabling yet rare disorder is limited and founded on a weak evidence base. The conclusion that corticosteroid treatment offers significant short-term benefit is based on sources of evidence …
Competing interests: None.